CD8A and cytomegalovirus infection: Thus, short-term treatment of patients with checkpoint inhibitors during a recurrent EBV and/or CMV infection could be a means to augment efficacy of exhausted virus-specific CD8+ T cells and thus reduce EBV and CMV related morbidity.